Key result
WCD successfully converts all life-threatening ventricular arrhythmias in the ~1% of pediatric patients receiving appropriate shocks.
Why the study?
Certain pediatric patients are at risk for sudden cardiac death and the effectiveness, safety, and compliance of the wearable cardioverter-defibrillator in this population needed evaluation.
Is the wearable cardioverter-defibrillator (WCD) safe, effective, and complied with in pediatric patients at risk for sudden cardiac death?
Cohort
Yes
Is the wearable cardioverter-defibrillator (WCD) safe, effective, and complied with in pediatric patients at risk for sudden cardiac death?
The wearable cardioverter-defibrillator is a safe and effective bridge therapy with adequate compliance for treating life-threatening ventricular arrhythmias in pediatric patients.
Answers are grounded in this paper and cite their sources.
Supports WCD consideration as bridge in pediatric SCD risk; leaves open need for RCTs to confirm efficacy.
BACKGROUND: Certain pediatric patients are at risk for sudden cardiac death. The wearable cardioverter-defibrillator (WCD) can be used in clinical situations in which implantable cardioverter-defibrillator placement is not ideal. The objectives of the study are to examine the effectiveness, safety, and compliance of the WCD in the identification and treatment of life-threatening ventricular arrhythmias in pediatric patients. METHODS: All United States pediatric patients <18 years who wore a WCD, from 2009 to 2016 were retrospectively reviewed. There were 7 deaths (1.5%); all not wearing WCD at time of death. Eight patients (1.8%) received at least 1 WCD shock treatment. Of the 6 patients (1.3%) who had appropriate therapy, there were 7 episodes of either polymorphic ventricular tachycardia or ventricular fibrillation with a total of 13 treatments delivered. All episodes were successfully converted and the patients survived. CONCLUSIONS: The WCD has overall adequate compliance with appropriate wear times and wear durations in pediatric patients. The WCD is safe and effective in treating ventricular arrhythmias that can lead to sudden cardiac death in pediatric patients.
No takes yet. Share an insight, caveat, or question.
Spar et al. (2018) conducted a cohort in Risk for sudden cardiac death. Wearable cardioverter-defibrillator (WCD) was evaluated on Appropriate therapy for life-threatening ventricular arrhythmias. The wearable cardioverter-defibrillator provided appropriate shock therapy to 1.3% of pediatric patients, successfully converting all episodes of life-threatening ventricular arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: